VTYX supply chain intelligence for Ventyx Biosciences Inc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Ventyx Biosciences Inc (VTYX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BAYSIDE | BAYSIDE | 90% | Expense recognized by the Company under the related party Support Services Agreement with Bayside was as follows (in thousands): Three months ended Nine months ended September 30, September 30, 2025 … |
| SANOFI | SANOFI | 90% | In connection with the Securities Purchase Agreement, the Company granted Sanofi a right of first negotiation ("ROFN") for a license, grant or transfer, including by option or sale, or any rights to … |
| JEFFERIES | JEFFERIES | 85% | In December 2022, the Company entered into an Open Market Sales Agreement SM ("Sales Agreement") with Jefferies, as sales agent, pursuant to which the Company may offer and sell in an at-the-market o… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from VTYX graph: and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapie… |
| BMY | Bristol-Myers Squibb Company | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from VTYX graph: and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therap… |
| BMYMP | Bristol-Myers Squibb Co | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| CNTB | Connect Biopharma Holdings Limited | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| CNTB | Connect Biopharma Holdings Limited | 72% | Reciprocal relationship from CNTB graph: Reciprocal relationship from VTYX graph: and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapi… |
| GILD | Gilead Sciences, Inc. | 72% | Holdings Limited, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals N.V., Merck & Co., Inc., Pfizer Inc., Protagonist Therapeutics, Inc., RedHill Biopharma Ltd., Seres Therapeutics,… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from GILD g… |
| MCRB | Seres Therapeutics, Inc. | 72% | Reciprocal relationship from MCRB graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics,… |
| MCRB | Seres Therapeutics, Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merc… |
| MRK | Merck & Co., Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | Reciprocal relationship from NBIX graph: Reciprocal relationship from VTYX graph: ket disruptions, whether as a result of the military conflict between Russia and Ukraine and effects of the Russian s… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | ket disruptions, whether as a result of the military conflict between Russia and Ukraine and effects of the Russian sanctions, geopolitical tensions, volatile changes to inflation or otherwise, are i… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | Reciprocal relationship from PTGX graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics,… |
| RDHL | RedHill Biopharma Ltd. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| RDHL | RedHill Biopharma Ltd. | 72% | Reciprocal relationship from RDHL graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics,… |
| SNYNF | Sanofi | 72% | nical studies and clinical trials. We have funded our operations primarily through equity and debt financings. We do not have any products approved for sale and have not generated any revenue from pr… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VTYX graph: nical studies and clinical trials. We have funded our operations primarily through equity and debt financings. We do… |
| TBPH | Theravance Biopharma, Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| TBPH | Theravance Biopharma, Inc. | 72% | Reciprocal relationship from TBPH graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Me… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from VTYX graph: and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therap… |
| LLY | Eli Lilly and Company | 62% | Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY grap… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LLY | Eli Lilly and Company | 92% | Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each share of the Company’s common stock, par v… |
| LLY | Eli Lilly and Company | 92% | Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Pursuant to the Merger Agreement, and… |
| BMY | Bristol-Myers Squibb Company | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from VTYX graph: and evaluation of individual patient … |
| BMYMP | Bristol-Myers Squibb Co | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from VTYX graph: and evaluation of individual pati… |
| CNTB | Connect Biopharma Holdings Limited | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| CNTB | Connect Biopharma Holdings Limited | 72% | Reciprocal relationship from CNTB graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from CNTB graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from CNTB g… |
| GILD | Gilead Sciences, Inc. | 72% | Holdings Limited, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals N.V., Merck & Co., Inc., Pfizer Inc., Protagonist Therapeutics, Inc., RedHill Biopharma Ltd., Seres Therapeutics,… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from VTYX graph: Holdings Limited, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals N.V., Merck & Co., Inc., Pfizer… |
| MCRB | Seres Therapeutics, Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| MCRB | Seres Therapeutics, Inc. | 72% | Reciprocal relationship from MCRB graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from MCRB graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from MCRB g… |
| MRK | Merck & Co., Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, … |
| NBIX | Neurocrine Biosciences, Inc. | 72% | ket disruptions, whether as a result of the military conflict between Russia and Ukraine and effects of the Russian sanctions, geopolitical tensions, volatile changes to inflation or otherwise, are i… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | Reciprocal relationship from NBIX graph: Reciprocal relationship from VTYX graph: ket disruptions, whether as a result of the military conflict between Russia and Ukraine and effects of the Russian s… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | Reciprocal relationship from PTGX graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Me… |
| RDHL | RedHill Biopharma Ltd. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| RDHL | RedHill Biopharma Ltd. | 72% | Reciprocal relationship from RDHL graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Me… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | nical studies and clinical trials. We have funded our operations primarily through equity and debt financings. We do not have any products approved for sale and have not generated any revenue from pr… |
| TBPH | Theravance Biopharma, Inc. | 72% | ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandion Therapeutics, Inc., RedHill Biopharma L… |
| TBPH | Theravance Biopharma, Inc. | 72% | Reciprocal relationship from TBPH graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics,… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cyclosporine, apremilast or biologic immune m… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from TKPH… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VTYX-DEBT | Debt stack $10.0M | 90% | Market cache reports total debt of $10.0M. |
| VTYX-DEBT-13467 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VTYX-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 7 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 |